Published in J Clin Oncol on November 01, 1989
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med (2011) 2.32
Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 2.04
BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood (2010) 1.68
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica (2010) 1.54
Diffuse cavitary lung lesions. Pediatr Radiol (2009) 1.45
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm (2010) 1.43
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol (2012) 1.37
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica (2014) 1.31
(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging (2010) 1.30
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist (2012) 1.18
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging (2011) 1.17
Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis (2013) 1.15
Orbital lymphoma: role of radiation. Indian J Ophthalmol (2009) 1.13
Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer (2003) 1.13
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol (2004) 1.11
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol (2010) 1.11
Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One (2012) 1.11
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 1.10
Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.06
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med (2011) 1.04
Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol (2011) 1.02
Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2006) 1.02
Hepatitis viruses and non-Hodgkin's lymphoma: A review. World J Virol (2012) 0.99
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol (2009) 0.99
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 0.98
Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol (1990) 0.97
The Cotswolds report on the investigation and staging of Hodgkin's disease. Br J Cancer (1990) 0.97
Hodgkin's Lymphoma: A Review of Neurologic Complications. Adv Hematol (2010) 0.97
Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2003) 0.96
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol (2011) 0.91
Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist (2010) 0.91
PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging (2007) 0.90
Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. Eur Radiol (2014) 0.90
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer (2004) 0.90
On the added value of baseline FDG-PET in malignant lymphoma. Mol Imaging Biol (2009) 0.89
Clinical utility of ¹⁸F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma. Br J Radiol (2012) 0.89
Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World J Gastroenterol (2014) 0.89
How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol (2011) 0.89
Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol (2014) 0.88
Imaging in oncology--over a century of advances. Nat Rev Clin Oncol (2012) 0.87
The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr (2013) 0.86
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer (2014) 0.86
Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev (2013) 0.86
Role of chemotherapy in Hodgkin's lymphoma. Cancer J (2009) 0.86
Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol (2015) 0.85
Current status of PET/CT in the diagnosis and follow up of lymphomas. Rev Bras Hematol Hemoter (2011) 0.84
Extranodal natural killer/T-cell lymphoma, nasal type, involving the skin, misdiagnosed as nasosinusitis and a fungal infection: A case report and literature review. Oncol Lett (2014) 0.84
How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models? Blood Cancer J (2012) 0.83
Treatment of osteonecrosis of the femoral head in lymphoma patients by free vascularised fibular grafting. Int Orthop (2010) 0.83
Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma. Adv Hematol (2010) 0.82
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol (2012) 0.82
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer (2005) 0.82
Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol (2015) 0.81
Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol (2013) 0.81
Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer (1997) 0.81
Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil. Clinics (Sao Paulo) (2009) 0.81
State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". Front Oncol (2013) 0.81
Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study. World J Surg Oncol (2013) 0.81
Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging (2003) 0.80
A Case of Malignant T-Cell Lymphoma of Gastric Origin Accompanied by Pyothorax. Case Rep Gastroenterol (2009) 0.80
Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. Croat Med J (2008) 0.80
Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement. World J Gastroenterol (2012) 0.80
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica (2010) 0.80
PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males. BMC Med Genet (2010) 0.80
Imagine a world without cancer. BMC Cancer (2014) 0.79
Intestinal Behçet's disease associated with non-Hodgkin's lymphoma. J Gastroenterol (1997) 0.79
Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT. Medicine (Baltimore) (2014) 0.79
Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An (18)F-FDG PET/CT study. Oncol Lett (2014) 0.79
Primary hepatic lymphoma with spindle cell components: a case report. Virchows Arch (2006) 0.79
Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br J Cancer (1993) 0.79
Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging (2014) 0.78
SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. Clin Transl Oncol (2015) 0.78
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica (2016) 0.78
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. PLoS One (2015) 0.78
Rituximab-including combined modality treatment for primary thyroid lymphoma: an effective regimen for elderly patients. Thyroid (2014) 0.78
Peripheral T-cell lymphoma with hypercalcemic crisis as a primary symptom accompanied by polymyositis: A case report and review of the literature. Oncol Lett (2014) 0.78
2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma. World J Radiol (2013) 0.78
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol (2016) 0.78
Primary breast diffuse large B cell lymphoma - report of 6 cases from South India with review of literature. Indian J Surg Oncol (2013) 0.78
Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature. Oncol Lett (2015) 0.78
Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother (2010) 0.78
Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009. Acta Oncol (2014) 0.77
Clinical features and outcome of primary pancreatic lymphoma. Ann Surg Oncol (2014) 0.77
PET in lymphoma. Cancer Imaging (2006) 0.77
Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am (2015) 0.77
Radiographic enlargement of mandibular canal as first feature of non-Hodgkin's lymphoma. Dentomaxillofac Radiol (2010) 0.77
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Br J Cancer (1998) 0.77
Characteristics of cryopreserved semen from men with lymphoma. J Assist Reprod Genet (2000) 0.77
Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. Ann Nucl Med (2014) 0.76
Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging (2006) 0.76
Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. Nucl Med Mol Imaging (2014) 0.76
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol (1991) 4.22
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Of scientific physicians and evidence-based medicine. Int J Radiat Oncol Biol Phys (2001) 3.94
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors. Cancer (1969) 3.29
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res (1994) 3.20
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol (1994) 2.94
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
Low-dose risk assessment. Radiat Res (2007) 2.88
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med (1992) 2.79
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol (1994) 2.59
Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol (2001) 2.55
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Repair of potentially lethal radiation damage in vitro and in vivo. Radiology (1973) 2.43
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Lymphoid cellular responses in the blood after immunization in man. J Exp Med (1969) 2.25
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood (1990) 2.24
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Cancer of the breast: the past decade (first of two parts). N Engl J Med (1980) 2.14
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14